Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Carcinoma, Renal Cell 2Neoplasms 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1

Interventions

blinatumomab 6Cyclophosphamide 5Rituximab 4Tacrolimus 3ponatinib 2fludarabine 2denileukin diftitox 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Everolimus 2Etoposide 2Doxorubicin 2Darbepoetin alfa 2Cytarabine 2Busulfan 2Brentuximab Vedotin 2Antilymphocyte Serum 2Alemtuzumab 2tetulomab tetraxetan lu-177 1ruxolitinib 1pembrolizumab 1pegaspargase 1ibrutinib 1ibritumomab tiuxetan 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoproliferative Disorders × Interferons × Clear all
NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
94 enrolled 20 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡